Life Sciences 28. March 2023 Thermosome receives BfArM approval Thermosome receives approval to conduct a phase 1 trial with its lead program THE001 in patients with soft tissue sarcoma.
Life Sciences 23. March 2023 Hemotune launches feasibility project with AstraZeneca hemotune initiates a joint feasibility project for its HemoSystem with the renowned pharmaceutical company AstraZeneca.
Life Sciences 23. March 2023 Follow-on investment in Lunaphore OCCIDENT participated in this Series D1 totaling 40 million Swiss francs under the lead of Ernst-Göhner Stiftung Beteiligungen (EGSB).
Life Sciences 19. December 2022 Follow-up Investment in Resistell OCCIDENT has been invested in Resistell since the seed financing and is now again participating in the first tranche of 8.5 million of the Series B.
Life Sciences 20. September 2022 Initial investment in Avelo OCCIDENT further strengthens its portfolio in the field of diagnostics and leads Avelo’s oversubscribed 2.2 million seed financing round.
Life Sciences 19. September 2022 Successful Exit Versantis French buyer GENFIT, a late-stage biopharmaceutical company, aims to strengthen its position as a leader in acute-on-chronic liver failure (ACLF).
Life Sciences 14. July 2022 adivo achieves two major milestones Our portfolio company adivo, focusing on developing the next generation of species-specific targeted drugs for companion animals, has announced the achievements of two major milestones.
Life Sciences 7. June 2022 mk2 announces joint development project mk2 Biotechnologies, WACKER and the Technical University of Munich (TUM) today announced their joint project for various applications.
Life Sciences 3. May 2022 Follow-up investment in Tubulis OCCIDENT participated in this € 60 million Series B led by Andera Partners with participation from new investors Evotec and Fund+.